Dinesh Rakheja
Overview
Explore the profile of Dinesh Rakheja including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
194
Citations
4176
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang A, Fairhurst A, Liu K, Wakeland B, Barnes S, Malladi V, et al.
Commun Biol
. 2024 Nov;
7(1):1446.
PMID: 39506084
Although significant progress has been achieved in elucidating the genetic architecture of systemic lupus erythematosus (SLE), identifying genes underlying the pathogenesis has been challenging. The NZM2410-derived lupus susceptibility Sle3 locus...
2.
Jasti J, Zhong H, Panwar V, Jarmale V, Miyata J, Carrillo D, et al.
ArXiv
. 2024 Jun;
PMID: 38855551
Background: Predictive biomarkers of treatment response are lacking for metastatic clearcell renal cell carcinoma (ccRCC), a tumor type that is treated with angiogenesis inhibitors, immune checkpoint inhibitors, mTOR inhibitors and...
3.
Collins R, Gee R, Sanchez M, Tozandehjani S, Bayat T, Breznik B, et al.
bioRxiv
. 2024 May;
PMID: 38798351
Background: Medulloblastoma (MB) is the most malignant childhood brain cancer. Group 3 MB subtype accounts for about 25% of MB diagnoses and is associated with the most unfavorable outcomes. Herein,...
4.
Kapur P, Zhong H, Le D, Mukhopadhyay R, Miyata J, Carrillo D, et al.
JCI Insight
. 2024 May;
9(10).
PMID: 38775158
Sarcomatoid dedifferentiation is common to multiple renal cell carcinoma (RCC) subtypes, including chromophobe RCC (ChRCC), and is associated with increased aggressiveness, resistance to targeted therapies, and heightened sensitivity to immunotherapy....
5.
Kundu A, Brinkley G, Nam H, Karki S, Kirkman R, Pandit M, et al.
J Clin Invest
. 2024 May;
134(13).
PMID: 38743486
Tumor cells are known to undergo considerable metabolic reprogramming to meet their unique demands and drive tumor growth. At the same time, this reprogramming may come at a cost with...
6.
Prakasam G, Mishra A, Christie A, Miyata J, Carrillo D, Tcheuyap V, et al.
J Clin Invest
. 2024 Feb;
134(7).
PMID: 38386415
Translocation renal cell carcinoma (tRCC) most commonly involves an ASPSCR1-TFE3 fusion, but molecular mechanisms remain elusive and animal models are lacking. Here, we show that human ASPSCR1-TFE3 driven by Pax8-Cre...
7.
Yang D, Zhou Q, Furman-Cline L, Cheng X, Luo D, Lai H, et al.
JCO Clin Cancer Inform
. 2023 Nov;
7:e2300104.
PMID: 37956387
Purpose: Osteosarcoma research advancement requires enhanced data integration across different modalities and sources. Current osteosarcoma research, encompassing clinical, genomic, protein, and tissue imaging data, is hindered by the siloed landscape...
8.
Zhang C, Chu A, Boriack R, Collins R, Xu J, Oliver D, et al.
EJHaem
. 2023 Aug;
4(3):723-727.
PMID: 37601838
This study investigates whether serum D-2HG (D-2-hydroxyglutarate) produced by the mutated isocitrate dehydrogenase (IDH) can predict mutations in acute myeloid leukemia (AML) at diagnosis. D-2HG and L-2HG are measured by...
9.
Jones B, Han J, Zhang H, Hammer R, Evers B, Rakheja D, et al.
Genes Dev
. 2023 Aug;
37(13-14):661-674.
PMID: 37553261
MicroRNAs (miRNAs) are post-transcriptional regulators of gene expression that play critical roles in development and disease. Target-directed miRNA degradation (TDMD), a pathway in which miRNAs that bind to specialized targets...
10.
Jones B, Han J, Zhang H, Hammer R, Evers B, Rakheja D, et al.
bioRxiv
. 2023 Jul;
PMID: 37425885
MicroRNAs (miRNAs) are post-transcriptional regulators of gene expression that play critical roles in development and disease. Target-directed miRNA degradation (TDMD), a pathway in which miRNAs that bind to specialized targets...